Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
Jay Visaria, Chioma Uzoigwe, Caroline Swift, Tam Dang‐Tan, Yurek Paprocki, Vincent J. Willey
Topics & Concepts
SemaglutideMedicineType 2 diabetesPopulationInternal medicineGlucagon-like peptide 1 receptorDiabetes mellitusExenatideMedical prescriptionEndocrinologyAgonistPharmacologyLiraglutideEnvironmental healthReceptorDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and Research